Benzinga's Top Initiations

Analysts at Piper Jaffray initiated coverage on Theravance Biopharma Inc TBPH with an Overweight rating. The price target for Theravance Biopharma is set to $42. Theravance Biopharma shares closed at $25.10 on Wednesday.
B. Riley initiated coverage on Viveve Medical Inc VIVE with a Buy rating. The price target for Viveve Medical is set to $8. Viveve Medical shares closed at $4.45 on Wednesday.
Analysts at Deutsche Bank initiated coverage of Alexion Pharmaceuticals, Inc. ALXN with a Buy rating. Alexion Pharmaceuticals shares closed at $127.74 on Wednesday.
Analysts at Citigroup assumed coverage of SemGroup Corp SEMG with a Neutral rating. The price target for SemGroup is set to $34. SemGroup shares closed at $30.35 on Wednesday.
Analysts at Deutsche Bank initiated coverage on Halozyme Therapeutics, Inc. HALO with a Buy rating. Halozyme Therapeutics shares closed at $8.32 on Wednesday.
Analysts at Aegis Capital initiated coverage on Cynosure, Inc. CYNO with a Buy rating. The price target for Cynosure is set to $60. Cynosure shares closed at $41.00 on Wednesday.
Analysts at Credit Suisse assumed coverage on Sunrun Inc RUN with an Outperform rating. The price target for Sunrun is set to $18. Sunrun shares closed at $4.63 on Wednesday.
Analysts at Deutsche Bank initiated coverage on Ariad Pharmaceuticals, Inc. ARIA with a Hold rating. The price target for Ariad Pharmaceuticals is set to $9.50. Ariad Pharmaceuticals shares closed at $9.01 on Wednesday.